Egalet Corporation (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, announced that a national pharmacy benefit manager (PBM) covering 3.5 million member lives has placed Sprix (ketorolac tromethamine) nasal spray in a tier 2 preferred position and Arymo ER (morphine sulfate) extended-release (ER) tablets for oral use only –CII in a tier 3 unrestricted position effective immediately.
"The coverage of Sprix and Arymo ER by this national PBM is an important development given our strategy to expand payer coverage of our products," said Patrick Shea, chief commercial officer of Egalet. "With this national PBM and the regional plans recently covering our products, we are beginning to gain traction to better enable us to bring our products to the healthcare providers treating the patients who might need them."
Arymo ER is a US Food and Drug Administration (FDA) approved abuse-deterrent (AD) opioid indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Arymo ER has physical and chemical properties expected to make abuse by injection difficult. AD properties do not prevent or reduce the risk of addiction. Abuse of Arymo ER by injection, as well as by the oral and nasal routes, is still possible.
Sprix (ketorolac tromethamine) is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. Sprix is not for use in pediatric patients less than 2 years of age.